Introduction: HLA-matched sibling donor (MSD) hematopoietic stem cell transplant is curative in
>92% of patients with sickle cell disease (SCD) but only 18% have MSD. Unrelated cord
blood transplantation (UCBT) expands donor options but is associated with high graft
rejection rates (50–62%). We hypothesized that a previously used reduced intensity
conditioning (RIC) regimen when combined with thiotepa would have acceptable toxicity
and support donor engraftment after UCBT for SCD.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
